DUSA Pharmaceuticals Inc. Board of Directors under Investigation for
Potential Breaches of Fiduciary Duty by Glancy Binkow & Goldberg LLP
LOS ANGELES -- November 08, 2012
Glancy Binkow & Goldberg LLP announces that it is investigating potential
claims against the Board of Directors of DUSA Pharmaceuticals Inc. (“DUSA” or
the “Company”) (Nasdaq: DUSA) related to the proposed acquisition of the
Company by Sun Pharmaceutical Industries Ltd. The transaction is valued at
approximately $230 million or $8.00 per share.
This investigation concerns whether the Board of Directors of DUSA breached
their fiduciary duties to stockholders by failing to adequately shop the
Company before agreeing to enter into the proposed transaction, and whether
the Company has disclosed all material information to shareholders about the
transaction. The Company has seen substantial recent growth. Its share price
skyrocketed from $4.89 on June 19, 2012 to $7.00 on October 16, 2012. Further,
at least one analyst has set a target price for the Company’s stock at $9.50.
If you are a shareholder of DUSA, if you have information or would like to
learn more about our investigation, or if you wish to discuss these matters or
have any questions concerning this announcement or your rights or interests
with respect to these matters, please contact Louis Boyarsky, Esquire, Glancy
Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, CA
90067, by telephone at (310) 201-9150 or Toll Free at (888) 773-9224 or by
email to email@example.com.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Glancy Binkow & Goldberg LLP
Louis Boyarsky, Esquire
Press spacebar to pause and continue. Press esc to stop.